Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 8 patients

B. Brihaye¹, A. Aouba¹, C. Pagnoux¹, P. Cohen¹, F. Lacassin², L. Guillevin¹

¹French Vasculitis Study Group, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Université Paris 7–René-Descartes, Paris, France; ²Department of Internal Medicine, Hôpital Gaston-Bourret, Centre Hospitalier Territorial Nouvelle-Calédonie, New Caledonia.


Please address correspondence to: Pr L. Guillevin, Department of Internal Medicine, Hôpital Cochin, 27, rue duaubourg Saint-Jacques, 75679 Paris Cedex 14, France. E-mail: loic.guillevin@cch.aphp.fr

Received on August 18, 2006; accepted in revised form on February 16, 2007.


© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2007.

Key words: Wegener’s granulomatosis, anti-neutrophil cytoplasm antibodies, vasculitis, rituximab, therapy.

ABSTRACT

Objective. Rituximab, an anti-CD20 biotherapy, has been effective against refractory and/or relapsing Wegener’s granulomatosis (WG). But the frequency of and time to responses to rituximab, and its effects on various clinical WG manifestations remain to be thoroughly evaluated.

Methods. Retrospective study of 8 patients with refractory/relapsing WG. In addition to their ongoing therapy, 7 patients received rituximab (375 mg/m² weekly for 4 weeks) and another received 2 rituximab infusions (1 g on days 1 and 15). Disease activity was assessed using BVAS 2003 before and 6 months after the first rituximab infusion.

Results. The median BVAS before rituximab was 14.3 (range 4–30). At 6 months, 5/8 patients had BVAS=0; 3/8 were in complete remission; 3/8 in partial remission (lung nodules persisted in 2 patients, scored 0 in BVAS); 2/8 did not respond. One patient relapsed 1 year after stopping rituximab and responded successfully to a second cycle. Dissociated responses of constitutional and ‘vasculitis’ symptoms, as opposed to granulomatous manifestations, were observed: the former regressed within days or weeks, while the latter regressed more slowly, over several months. Tolerance was good for 7 patients but 1 developed an arthralgia during the last 3 infusions. Corticosteroids could be tapered in all patients.

Conclusion. Rituximab, when prescribed in conjunction with corticosteroids and immunosuppressants to treat refractory/relapsing WG, was able to improve clinical outcome. But the dissociation of response times in patients with predominantly granulomatous manifestations, as opposed to vasculitis symptoms, merits further study before an optimal rituximab regimen can be defined.

Introduction

Wegener’s granulomatosis (WG) is characterized by around 50% relapses despite prolonged immunosuppressant therapies (1). Cyclophosphamide combined with corticosteroids (CS) remains the most effective induction regimen and should be followed by a prolonged less toxic treatment to maintain remission (2). In the case of relapses occurring under or immediately after withdrawing therapy, or when patients do not respond to several lines of immunosuppressants (IS), alternative therapies are needed. They include other combinations of IS or intensification of the previously prescribed drugs. Biotherapies, like intravenous immunoglobulins (3), anti-tumor necrosis factor-α (4, 5) and, more recently, anti-CD20 (6) antibodies, can also be prescribed instead of or in addition to conventional treatments. Herein, we report our experience with 8 patients who received rituximab for WG relapses occurring despite optimal conventional treatment and/or other biotherapies.

Patients and methods

Patients’ characteristics, affected organs, indication of rituximab and anti-neutrophil cytoplasm antibody (ANCA) status are reported in Table I.

Patients

We retrospectively reviewed the medical files of the 8 patients followed in our department who received rituximab between May 2002 and December 2005. All of them fulfilled the ACR 1990 classification (7) and the Chapel Hill Nomenclature (8) criteria. WG was biopsy-proven for all patients. At diag-
Rituximab in Wegener’s granulomatosis – 6 months. Patient 1

Assessment
Retrospectively collected information included: clinical manifestations, routine biological parameters, ANCA results (Indirect immunofluorescence and ELISA); computed tomography (CT) scans of the chest, sinuses and orbits, if appropriate, were performed 4 months after the first rituximab infusion, then every 3–6 months, according to the clinical symptoms. Circulating B-lymphocyte counts, assessed by flow cytometry, were not systematically determined and were not retained as a parameter for drug reinfusion.

All patients were evaluated at 6 months and then in a non-uniform fashion. WG activity was assessed with the 2003 version of the Birmingham vasculitis activity score (BVAS) (10). According to BVAS, complete remission was defined as 0 points, indicating the absence of new symptoms or worsening of those already present. Partial remission was defined as persistent disease activity for no more than 1 item. We considered patients with persistent lung nodules, even if they had decreased in size, to be in partial remission, even though this situation is scored BVAS = 0. The day of the first rituximab infusion was considered day 1.

Results
The main findings are summarized in Table I.

Overall response to treatment
At 6 months, 5 of our 8 patients (no. 1, 2, 4, 5 and 6) had BVAS = 0 but only patients 2, 5 and 6 were considered to be in complete remission, because patients 1, 3 and 4 had persistent lung nodules, which we defined as partial remission. Patients 7 and 8 did not respond to therapy. By the censoring date, patient 3, who had been in partial remission at 6 months, had entered complete remission.

Patient 1 entered complete remission 1 month after the first rituximab infusion. He relapsed 12 months after the 16th infusion and his pyoderma gangrenosum worsened, lung nodules appeared, and a high-degree atrioventricular block developed. Partial remission was obtained 2 months after starting a new course of a weekly rituximab infusion for 4 weeks.

ANCA status and biologic inflammatory parameters
Six patients were ANCA-positive at the onset of rituximab therapy and 3 became ANCA-negative at some time after starting rituximab. Rituximab contributed to complete remission for patients 3 and 6, and to partial remission for patient 1; all 3 were ANCA-negative when rituximab was administered.

In contrast, patient 7’s orbital pseudotumor was not affected but he became ANCA-negative.

Discussion
Herein, we described our experience with 8 patients with refractory-relapsing WG emphasizing the effect of rituximab on the various components of the disease. The overall response was good and complete or partial remissions were obtained in 6/8 patients. Pertinently, general symptoms tended to regress quickly, sometimes in only a few days after the first infusion. In contrast, WG

BRIEF PAPER

Rituximab in Wegener’s granulomatosis / B. Brihaye et al.
Table I. Detailed individual demographic, clinical, biological and outcome characteristics of the 8 patients with refractory/relapsing WG given rituximab.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at RTX start/sex</th>
<th>Months since diagnosis</th>
<th>Previously prescribed IS</th>
<th>Ineffective regimens at RTX onset</th>
<th>Active organ involvement at RTX onset</th>
<th>Total no. of RTX pulses</th>
<th>ANCA status Before RTX</th>
<th>ANCA status After RTX</th>
<th>BVAS baseline/6 mo</th>
<th>Concomitant drugs</th>
<th>Status at censoring date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44/M</td>
<td>184</td>
<td>oral CYC, IVIg, AZA, MMF, MTX, infliximab</td>
<td>MTX: 12.5 mg/wk; MMF: 3 g/d; CS: 5 mg/d</td>
<td>PG, ENT</td>
<td>16</td>
<td>yes</td>
<td>no (17 mo)</td>
<td>13.0 CR</td>
<td>MTX: 10 mg/wk; MMF: 3 g/d</td>
<td>CR at 2 mo; relapse 12 mo after stopping RTX</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>heart, L, PG</td>
<td>4</td>
<td>no</td>
<td>no</td>
<td>15.0 PR</td>
<td>MTX: 10 mg/wk; MMF: 3 g/d</td>
<td>PR at 6 mo (persistent lung nodules)</td>
</tr>
<tr>
<td>2</td>
<td>42/M</td>
<td>30</td>
<td>IV then oral CYC</td>
<td>oral CYC: 200</td>
<td>E, ENT, K, CS: 90 mg/d perforation</td>
<td>5</td>
<td>yes</td>
<td>no (12 mo)</td>
<td>3.00 CR</td>
<td>CS 5 mg/d; MMF 2 g/d; IVIg</td>
<td>CR at 24 mo</td>
</tr>
<tr>
<td>3</td>
<td>55/M</td>
<td>88</td>
<td>IV CYC, MMF, oral CYC, MTX, IVIg, infliximab</td>
<td>infliximab; MTX: 25 mg/wk; CS: 25 mg/d</td>
<td>ENT, L, PNS</td>
<td>5</td>
<td>no</td>
<td>no</td>
<td>19.3 PR</td>
<td>CS 5 mg/d; MTX: 20 mg/wk; leflunomide: 10 mg/d</td>
<td>CR at 18 mo</td>
</tr>
<tr>
<td>4</td>
<td>56/M</td>
<td>109</td>
<td>IV then oral CYC, AZA, IVIg, MMF</td>
<td>MMF: 2 g/d; CS: 5 mg/d</td>
<td>L, K</td>
<td>8</td>
<td>yes</td>
<td>yes</td>
<td>13.0 PR</td>
<td>CS 5 mg/d</td>
<td>PR at 26 mo (persistent lung nodules)</td>
</tr>
<tr>
<td>5</td>
<td>44/F</td>
<td>160</td>
<td>Oral CYC, AZA, MTX, IVIg, IV CYC</td>
<td>IV CYC: 0.6 g/m2/15 d</td>
<td>ENT, 'strawberry' gingival hyperplasia</td>
<td>4</td>
<td>yes</td>
<td>no (3 mo)</td>
<td>8.0 CR</td>
<td>CS: 10 mg/d</td>
<td>CR at 7 mo</td>
</tr>
<tr>
<td>6</td>
<td>71/F</td>
<td>52</td>
<td>MTX, IV then oral CYC, IVIg</td>
<td>oral CYC: 125 mg/d; CS: 20 mg/d</td>
<td>ENT, L, PNS</td>
<td>4</td>
<td>no</td>
<td>no</td>
<td>22.0 CR</td>
<td>CS: 10 mg/d</td>
<td>CR at 7 mo</td>
</tr>
<tr>
<td>7</td>
<td>47/M</td>
<td>206</td>
<td>IV then oral CYC, MTX, AZA, etanercept</td>
<td>oral CYC: 100 mg/d etanercept, IV CS</td>
<td>E (orbital pseudotumor), ENT, CNS</td>
<td>4</td>
<td>yes</td>
<td>yes</td>
<td>44 failure</td>
<td>CS: 20 mg/d; AZA: 150 mg/d; MTX: 15 mg/wk; IVIg</td>
<td>unchanged orbital pseudotumor at 13 mo</td>
</tr>
<tr>
<td>8</td>
<td>38/F</td>
<td>108</td>
<td>oral the IV CYC, MTX, etanercept, infliximab, IVIg, AZA</td>
<td>AZA: 150 mg/d</td>
<td>orbital pseudotumor relapse after enucleation</td>
<td>2</td>
<td>yes</td>
<td>no (3 mo)</td>
<td>44 failure</td>
<td>unchanged orbital pseudotumor at 6 mo</td>
<td></td>
</tr>
</tbody>
</table>

RTX: rituximab; ANCA: antineutrophil cytoplasm antibodies; BVAS: Birmingham vasculitis activity score; AZA: azathioprine; (IV) CYC: (intravenous) cyclophosphamide; IVIg: intravenous immunoglobulin; MMF: mycophenolate mofetil; MTX: methotrexate; PG: pyoderma gangrenosum; E: eye; ENT: ear, nose, throat; K: kidney; L: lung; CNS: central nervous system; PNS: peripheral nervous system; CR: complete remission; PR: partial remission.
granulomatous manifestations did not respond in the same way. They responded to rituximab much later. Although rituximab failed to achieve remission in patients with orbital pseudotumors, the latter continued to diminish in size and orbital pain disappeared. Concerning lung nodules, no clinically marked size changes were observed during the first months after rituximab. But the patients became completely asymptomatic and granulomas progressively disappeared. The transient adjunction of methotrexate to the treatment regimen of 1 patient and leflunomide for another did seem not to have an effect on the long-term regression of lung nodules. Notably, the rapid attenuation of constitutional and vasculitis-related symptoms was not the consequence of CS, because the prednisone dose was increased for only 2 patients at the time rituximab was administered, and 3 patients were not even taking CS.

Almost all of the patients described by Keogh et al. (6, 11), Eriksson (12) and Stasi et al. (13) had achieved complete remission by 6 months. At the time of rituximab initiation, their patients were characterized by active organ involvement, mainly due to severe vasculitis (e.g., alveolar hemorrhage) or glomerulonephritis. In contrast, Aries et al. (14) reported the lack of rituximab efficacy in WG patients with refractory granulomatous manifestations. However, in the latter, the therapeutic response had been evaluated 4 weeks after the completion of the 4th rituximab pulse, which might have been too early to assess the efficacy of this biologic. In light of the slow regression of granulomatous disease under rituximab that we observed in our patients, rituximab efficacy on granulomatous manifestations should not be evaluated before 3 months or even before 6 months. If this approach is correct, it would mean that rituximab might not be appropriate, at least as the sole agent, when a granulomatous mass is organ-threatening (e.g., orbital pseudotumor and retrolubular optic neuritis). Should ongoing prospective clinical trials confirm the efficacy of rituximab, a further step would be to determine whether its combination with other treatment(s) could reduce the time to response for threatening granulomatous manifestations and/or enhance the expected effect of the anti-CD20 therapy. BVAS is usually used to assess the activity of ANCA-associated vasculitis. The absence of new/worsening manifestations generates a score of 0, which can be considered a complete remission. However, partial and complete remissions have been defined differently, depending on investigators’ choices. Based on our clinical experience, persistence of unchanged or only slightly diminished pulmonary nodules after 3 months of immunosuppressive therapy was associated with a high relapse rate. Therefore, we considered these patients to be in only partial remission. Among our 8 patients, 5 had BVAS = 0 but, in our opinion, 2 of them should be and were considered as being only in partial remission. Difficulties establishing a reliable scoring system for vasculitis activity were clearly emphasized by the Vasculitis Clinical Research Consortium (10).

We also observed that the response to treatment was sustained. One patient relapsed 1 year after stopping rituximab, despite maintenance IS therapy. But the patient responded well to a 2nd rituximab cycle. That case report might encourage clinicians to taper and/or stop IS and/or CS when patients have received/responded to rituximab because the IS maintenance therapy was ineffective and may subsequently appear unnecessary.

We observed that the response to rituximab in WG could be independent of ANCA status. Three of our patients were ANCA-negative when rituximab was administered and they responded to treatment. To the best of our knowledge, only 1 ANCA-negative patient with a sustained 3-year remission after rituximab has been reported (15). In contrast, our patient 8, who had an orbital pseudotumor, became ANCA-negative but was considered a clinical failure. These data challenge theories in which ANCA are key effectors in ANCA-associated vasculitis pathophysiology (16). In addition, our patients 2 and 5 remained ANCA-positive after rituximab treatment and throughout prolonged follow-up. Aries and colleagues (14) also found that ANCA titers were unchanged for 6 out of 8 patients after rituximab therapy. Pertinently, Browning postulated that rituximab acts directly on B lymphocytes and short-lived plasma cells that also express CD20, resulting in the rapid blockade or decrease of ANCA production, whereas long-lived plasma cells that have lost CD20 are not affected and can continue to produce ANCA (17). The results obtained by Keogh et al. (11), Eriksson (12) and Smith et al. (18) highlighted that clinical responses to rituximab were associated with effective B-lymphocyte depletion. All reported clinical relapses had been preceded by reconstitution of the B-lymphocyte counts, 6 to 12 months after starting the rituximab cycle.

Rituximab maintenance therapy might be a new alternative but, at present, no such recommendation can be made. For example, 1 rituximab infusion of 375 mg/m² could be systematically given at fixed intervals, 4-6 months, or new infusions could be prescribed only when circulating CD19-positive B cells reappeared in blood and/or when ANCA are again detected or their titer increases. Such an approach seems reasonable but relapses still occur in ANCA-negative patients. At present, we favor systematic readministration (every 4–6 months), until further experience with this agent justifies modifying this strategy.

In conclusion, rituximab, when prescribed in combination with CS and immunosuppressants for patients with refractory/relapsing WG despite optimal treatment, is able to improve dramatically the clinical outcome, especially for constitutional and vasculitis-related symptoms independently of ANCA status. In contrast, orbital pseudotumors responded late and very poorly, with responses remaining incomplete, but continued attenuation of the other granulomatous manifestations was observed.

References
Rituximab in Wegener’s granulomatosis / B. Brihaye et al.


